Loading...
•
Jun 30, 2020
Krystal Biotech Q2 2020 Earnings Report
Krystal Biotech reported its Q2 2020 financial results and provided an update on operational progress.
Key Takeaways
Krystal Biotech reported a net loss of $6.8 million for the second quarter of 2020. The company's cash, cash equivalents, and short-term investments totaled $297.2 million as of June 30, 2020. They are on track to initiate a Phase 1 trial of KB301 for an aesthetic indication in 2H 2020.
Initiated the pivotal GEM-3 clinical study evaluating B-VEC in DEB patients.
Announced enrollment of the first patient in the Phase 2 clinical study evaluating KB105 in ARCI patients.
On track to initiate a Phase 1 trial of KB301 for an aesthetic indication in 2H 2020.
Cash, cash equivalents and marketable securities of $297.2 million as of June 30, 2020.
Krystal Biotech
Krystal Biotech
Forward Guidance
Krystal Biotech is focused on advancing its clinical programs and expanding its pipeline.
Positive Outlook
- Initiation of GEM-3 study for B-VEC in DEB patients.
- Enrollment of first patient in Phase 2 study of KB105 in ARCI patients.
- On track to initiate Phase 1 trial of KB301 for aesthetic indications in 2H 2020.
- Anticipated BLA filing in 2021.
- Strong cash position to support clinical programs and pipeline expansion.
Challenges Ahead
- Uncertainties inherent in clinical trials.
- Availability and timing of data from clinical trials.
- Regulatory review uncertainties.
- Commercial potential of product candidates.
- Potential impact of COVID-19 on business operations.